ALYMSYS vs GILOTRIF

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. ALYMSYS and GILOTRIF are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	ALYMSYS	GILOTRIF
Rating	70/100	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BEVACIZUMAB-MALY	AFATINIB DIMALEATE
Manufacturer	Amneal	Boehringer Ingelheim
Dosage forms	Injectable	Tablet
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms	Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

alymsys gilotrif

Rating

70/100

72/100

Pharmacy pays

—

Type

Active ingredient

BEVACIZUMAB-MALY

AFATINIB DIMALEATE

Manufacturer

Amneal

Boehringer Ingelheim

Dosage forms

Injectable

Tablet

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

Frequently asked questions

Which is better-rated, Alymsys or Gilotrif?

By our independent rating, Gilotrif scores higher — 3.6 vs 3.5 out of 5 for Alymsys. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Alymsys and Gilotrif?

Alymsys contains Bevacizumab-Maly, while Gilotrif contains Afatinib Dimaleate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.